Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259610
Status:
COMPLETED
Last Update Posted:
2014-07-17
First Post:
2005-11-28
Brief Title:
Treatment of Early Aggressive Rheumatoid Arthritis TEAR
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
Treatment of Early Aggressive Rheumatoid Arthritis TEAR
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEAR
Brief Summary:
The purpose of this study is to 1to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2 to determine which combination of methotrexate therapy is better
Detailed Description:
The ultimate goal of RA is to eliminate symptoms restoring the patient to normal physical social emotional and vocational function and preserving the structure and integrity of joints While disease modifying anti-rheumatic drugs DMARDs have long been the cornerstone of RA therapy the limitations of DMARDs have become increasingly apparent and investigators continue to gain insight into the pathogenesis of this disease Recent evidence suggests that treatment earlier in the disease process with more aggressive approaches results in superior long-term outcomes compared to less intensive treatment regimens Specifically there is growing interest in the possibility that early aggressive treatment with combinations of DMARDs as initial treatment in efforts to potentially reduce the proportion of patients that advance to severe disability
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 20040391 | None | None | None |